Identification
NamePeginterferon alfa-2b
Accession NumberDB00022  (BTD00048, BIOD00048)
TypeBiotech
GroupsApproved
Description

Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [3]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C [2]. Peginterferon alfa-2b was used alongside Ribavirin with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [1].

Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2b and Ribavirin have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.

Protein structureDb00022
Related Articles
Protein chemical formulaNot Available
Protein average weight31000.0 Da
Sequences
>DB00022 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PegintronKitMerck Sharp & Dohme Limited2001-01-192017-06-21Us
PegintronKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
PegintronInjection, powder, lyophilized, for solution80 ug/.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Limited2001-01-192017-06-21Us
PegintronKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
PegintronKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
PegintronInjection, powder, lyophilized, for solution50 ug/.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
PegintronKitMerck Sharp & Dohme Limited2001-01-192017-06-21Us
PegintronInjection, powder, lyophilized, for solution120 ug/.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegintronInjection, powder, lyophilized, for solution150 ug/.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Limited2001-01-192017-06-21Us
SylatronKitMerck Sharp & Dohme Limited2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Limited2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Limited2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Limited2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Limited2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Limited2014-08-30Not applicableUs
Unitron PegPowder, for solution177.6 mcgSubcutaneousMerck Ltd.2001-03-272012-02-01Canada
Unitron PegPowder, for solution118.4 mcgSubcutaneousMerck Ltd.2001-03-272012-02-01Canada
Unitron PegPowder, for solution222 mcgSubcutaneousMerck Ltd.2001-03-272012-02-01Canada
Unitron PegPowder, for solution74 mcgSubcutaneousMerck Ltd.2001-03-272012-02-01Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PEG-IntronSchering Corp
Brand mixtures
NameLabellerIngredients
PegetronMerck Ltd.
Victrelis TripleMerck Ltd.
Categories
UNIIG8RGG88B68
CAS number215647-85-1
Pharmacology
Indication

Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.

Structured Indications
Pharmacodynamics

Peginterferon alfa-2b inhibits viral replication in infected cells, suppresses cell proliferation, induces apoptosis, and exerts an anti-angiogenic effect [FDA Label]. Exerts immunomodulatory effects such as enhancement of the phagocytic activity of macrophages, activation of NK cells, stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset. Also increases concentrations of effector proteins such as serum neopterin and 2'5' oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts.

Mechanism of action

Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor κB pathway.

TargetKindPharmacological actionActionsOrganismUniProt ID
Interferon alpha/beta receptor 1Proteinyes
agonist
HumanP17181 details
Interferon alpha/beta receptor 2Proteinyes
agonist
HumanP48551 details
Related Articles
Absorption

Peginterferon alfa-2b reaches peak plasma concentration 15-44 hours after subcutaneous administration [FDA Label]. The mean absorption half-life is 4.6 hours. After multiple doses the bioavailability of Peginterferon alfa-2b increases with trough concentrations at week 48 3-fold higher than those at week 4.

Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of elimination

Renal elimination accounts for 30% of Peginterferon alfa-2b elimination [FDA Label].

Half life

The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours [FDA Label].

Clearance

The estimated apparent clearance of Peginterferon alfa-2b is 22 milliters per hour per kilogram [FDA Label].

Toxicity

Peginterferon alfa-2b may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2b. Peginterferon alfa-2b may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2b causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2b. Peginterferon alfa-2b may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2b are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2b. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2b. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2b treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2b is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2b while pregant may result in delopmental abnormalities or death of the fetus.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Interferon lambda-3---(T;T) / (C;T) / (G;G) / (G;T)C > T / T > G Effect Directly StudiedLower odds of response Details
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Experimental, Illicit
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Peginterferon alfa-2b.Approved
AcetylcholineThe serum concentration of Acetylcholine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AjmalineThe serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2b.Experimental
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmoxapineThe serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmphetamineThe serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmsacrineThe serum concentration of Amsacrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AnagrelideThe serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.Approved
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AprindineThe serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ArformoterolThe serum concentration of Arformoterol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AtomoxetineThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2b.Investigational
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BenzatropineThe serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BepridilThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.Experimental, Investigational
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Peginterferon alfa-2b.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarmustineThe serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.Approved
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.Approved
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Peginterferon alfa-2b.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClenbuterolThe serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical
ClozapineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine.Approved
CodeineThe serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Peginterferon alfa-2b.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Peginterferon alfa-2b.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Peginterferon alfa-2b.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Withdrawn
DexmethylphenidateThe serum concentration of Dexmethylphenidate can be decreased when it is combined with Peginterferon alfa-2b.Approved
DextroamphetamineThe serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Peginterferon alfa-2b.Approved
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Peginterferon alfa-2b.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.Approved
DopamineThe serum concentration of Dopamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
DuloxetineThe serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.Approved
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.Approved
EncainideThe serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
EnclomipheneThe serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be decreased when it is combined with Peginterferon alfa-2b.Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
FluphenazineThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FormoterolThe serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GenisteinThe serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.Investigational
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
GuanabenzThe serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.Approved
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
HesperetinThe serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.Approved
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Peginterferon alfa-2b.Approved
LabetalolThe serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.Approved
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.Approved
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Peginterferon alfa-2b.Approved
LomefloxacinThe serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
LomustineThe serum concentration of Lomustine can be decreased when it is combined with Peginterferon alfa-2b.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Peginterferon alfa-2b.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Peginterferon alfa-2b.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MalathionThe serum concentration of Malathion can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MaprotilineThe serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical, Vet Approved
MenadioneThe serum concentration of Menadione can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MesoridazineThe serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b.Withdrawn
MethadoneThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.Approved
MethamphetamineThe serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
MethotrimeprazineThe serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
MethylphenidateThe serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MethyprylonThe serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Withdrawn
MetoclopramideThe serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Peginterferon alfa-2b.Approved
MinaprineThe serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MoclobemideThe serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
NabumetoneThe serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicergolineThe serum concentration of Nicergoline can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
Nitric OxideThe serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.Approved
NitrofuralThe serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.Approved
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
ParoxetineThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegloticaseThe therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Peginterferon alfa-2b.Withdrawn
PhenforminThe serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
PimozideThe serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PiperazineThe serum concentration of Piperazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.Approved
ProcainamideThe serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Peginterferon alfa-2b.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PseudoephedrineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Peginterferon alfa-2b.Approved
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.Approved
RemoxiprideThe serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
ResveratrolThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.Experimental, Investigational
RibavirinThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Peginterferon alfa-2b.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Peginterferon alfa-2b.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Peginterferon alfa-2b.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.Approved
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
SparteineThe serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.Approved
TegaserodThe serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
TelbivudineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.Approved, Investigational
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Peginterferon alfa-2b.Approved
TemafloxacinThe serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Peginterferon alfa-2b.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Peginterferon alfa-2b.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.Withdrawn
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Peginterferon alfa-2b.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TriamtereneThe serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Peginterferon alfa-2b.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Peginterferon alfa-2b.Approved
VadimezanThe serum concentration of ASA404 can be increased when it is combined with Peginterferon alfa-2b.Investigational
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348 ]
  2. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [PubMed:28497432 ]
  3. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
External Links
ATC CodesL03AB60 — Peginterferon alfa-2b, combinationsL03AB10 — Peginterferon alfa-2b
AHFS Codes
  • 08:18.20
PDB Entries
FDA labelDownload (1.69 MB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMelanoma1
1CompletedDiagnosticChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHepatitis C, Chronic1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentMelanoma2
1RecruitingTreatmentMelanoma1
1TerminatedTreatmentChronic Hepatitis C Infection1
1TerminatedTreatmentRenal Cancers1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnDiagnosticChronic Hepatitis C Virus (HCV) Infection1
1, 2CompletedTreatmentChronic Hepatitis C Infection1
1, 2CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2RecruitingTreatmentMelanoma / Renal Cell Adenocarcinoma1
1, 2RecruitingTreatmentMetastatic Melanoma1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentChronic Hepatitis C Infection1
2Active Not RecruitingTreatmentHIV-1 Infections1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of Skin1
2CompletedTreatmentChronic Hepatitis B Infection1
2CompletedTreatmentChronic Hepatitis C Infection3
2CompletedTreatmentChronic Hepatitis C Infection / HCV Infections / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentChronic Hepatitis C Infection / Hepatitis C, Chronic1
2CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection6
2CompletedTreatmentHCV Infections / Liver Cirrhosis, Experimental1
2CompletedTreatmentHealth Care Evaluation / Health Care Quality1
2CompletedTreatmentHepatitis C Infection1
2CompletedTreatmentHepatitis C, Chronic3
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLeukemias1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMelanoma2
2CompletedTreatmentPlexiform Neurofibroma1
2Not Yet RecruitingTreatmentAdvanced Cholangiocarcinoma1
2RecruitingTreatmentChildhood Craniopharyngioma1
2RecruitingTreatmentHIV Disease / HIV/AIDS1
2RecruitingTreatmentJuvenile Pilocytic Astrocytomas / Optic Pathway Gliomas1
2TerminatedTreatmentAnemias / Hypoxemia / Liver Diseases1
2TerminatedTreatmentHepatitis C, Chronic2
2TerminatedTreatmentLeukemia, Myeloid, Philadelphia-Positive1
2TerminatedTreatmentLeukemias1
2Unknown StatusTreatmentChronic Myeloid Leukemia (CML)1
2Unknown StatusTreatmentMelanoma1
2WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
2, 3CompletedTreatmentChronic Hepatitis C Infection / Hepatitis1
2, 3CompletedTreatmentFibrosis, Liver / Hepatitis C, Chronic1
2, 3TerminatedNot AvailableHepacivirus / Hepatitis C, Chronic1
2, 3WithdrawnTreatmentHepatitis C, Chronic1
3Active Not RecruitingTreatmentChronic Hepatitis C Infection / Hepatitis / Hepatitis C/ Human Immunodeficiency Virus Coinfection1
3Active Not RecruitingTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Osteosarcoma1
3CompletedPreventionHepatocellular,Carcinoma1
3CompletedTreatmentAids / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Hepatitis C Infection6
3CompletedTreatmentChronic Hepatitis C Infection / Coinfection / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection4
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Liver Cirrhosis1
3CompletedTreatmentFibrosis / Hepatitis / Hepatitis C, Chronic / Liver Cirrhosis1
3CompletedTreatmentHepatitis B, Chronic (CHB)1
3CompletedTreatmentHepatitis B,Chronic / Hepatitis D, Chronic1
3CompletedTreatmentHepatitis C, Chronic15
3CompletedTreatmentHepatitis C, Chronic / Liver Cirrhosis1
3CompletedTreatmentLeukemia,Myeloid, Chronic1
3CompletedTreatmentMelanoma / Neoplasms Metastasis1
3CompletedTreatmentGenotype 1 chronic hepatitis C infection1
3RecruitingTreatmentHepatitis B,Chronic1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3TerminatedTreatmentHepatitis B,Chronic1
3TerminatedTreatmentHepatitis C, Chronic2
3TerminatedTreatmentHepatitis C, Chronic / Liver Cirrhosis1
3Unknown StatusTreatmentChronic Hepatitis B Infection1
3Unknown StatusTreatmentGenotype 4 Chronic Hepatitis C Infection1
3WithdrawnTreatmentChronic Hepatitis C Infection1
3WithdrawnTreatmentChronic Hepatitis C Virus (HCV) Infection3
4Active Not RecruitingNot AvailableHepatitis C Infection / HIV Disease1
4CompletedNot AvailableHepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted1
4CompletedTreatmentAntiviral Agents / Chronic Liver Diseases (CLD) / Hepatitis C Virus (HCV) / Therapeutic Uses / Virus Hepatitis1
4CompletedTreatmentChronic Hepatitis B Infection1
4CompletedTreatmentChronic Hepatitis C Infection2
4CompletedTreatmentChronic Hepatitis C Infection / HIV Disease1
4CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
4CompletedTreatmentHepatitis C, Chronic3
4RecruitingTreatmentChronic Hepatitis B Infection1
4TerminatedTreatmentHepacivirus / Hepatitis C, Chronic / Human Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHepatitis C, Chronic3
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection / End Stage Renal Disease (ESRD)1
4Unknown StatusTreatmentHepatitis C Infection1
4WithdrawnTreatmentChronic Hepatitis C Infection1
Not AvailableCompletedNot AvailableChronic Hepatitis C Infection2
Not AvailableCompletedNot AvailableChronic Hepatitis C Infection / Chronic Hepatitis C Virus (HCV) Infection1
Not AvailableCompletedNot AvailableChronic Hepatitis C Infection / Chronic Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableChronic Hepatitis C Infection / Hepatitis C, Chronic9
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection1
Not AvailableCompletedNot AvailableGenotype 1 / HCV-1 / Hepatitis C, Chronic1
Not AvailableCompletedNot AvailableHepacivirus / Hepatitis C, Chronic4
Not AvailableCompletedNot AvailableHepatitis C Virus (HCV) / Hepatitis C, Chronic1
Not AvailableCompletedNot AvailableHepatitis C, Chronic9
Not AvailableCompletedNot AvailableHepatitis C, Chronic / Substance Abuse, Intravenous1
Not AvailableCompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingNot AvailableViral Hepatitis B1
Not AvailableRecruitingTreatmentHepatitis B,Chronic1
Not AvailableTerminatedNot AvailableHepacivirus / Hepatitis C, Chronic1
Not AvailableTerminatedNot AvailableHepatitis C, Chronic1
Not AvailableTerminatedTreatmentMalignant Lymphomas1
Not AvailableUnknown StatusBasic ScienceChronic HCV Infection / Nonalcoholic Steatohepatitis1
Not AvailableUnknown StatusTreatmentChronic Hepatitis B Infection1
Not AvailableWithdrawnNot AvailableChronic Hepatitis C Infection / Hepatitis C, Chronic1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule; powder, for solutionOral; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous120 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous150 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous50 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous80 ug/.5mL
Kit
Powder, for solutionSubcutaneous118.4 mcg
Powder, for solutionSubcutaneous177.6 mcg
Powder, for solutionSubcutaneous222 mcg
Powder, for solutionSubcutaneous74 mcg
Prices
Unit descriptionCostUnit
Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box2428.8USD kit
Peg-Intron Redipen 150 mcg/0.5ml Kit702.87USD kit
Peg-Intron 150 mcg Kit671.74USD kit
Peg-Intron Redipen 120 mcg/0.5ml Kit669.39USD kit
Peg-Intron redipen 150 mcg640.61USD redipen
Peg-Intron redipen 150 mcg 4pk640.6USD redipen
Peg-Intron 120 mcg Kit639.74USD kit
Peg-Intron Redipen 80 mcg/0.5ml Kit637.49USD kit
Peg-Intron redipen 120 mcg610.09USD redipen
Peg-Intron 80 mcg Kit609.26USD kit
Peg-Intron 50 mcg/0.5ml Kit607.19USD kit
Peg-Intron redipen 80 mcg581.02USD redipen
Peg-Intron 50 mcg kit553.4USD kit
Peg-Intron redipen 50 mcg553.4USD redipen
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341567 No2008-02-192025-02-19Canada
CA2329474 No0002-02-262016-10-31Canada
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °CBeldarrain, A. et al., Biochemistry 38:7865-7873 (1999)
isoelectric point5.99Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.
Gene Name:
IFNAR1
Uniprot ID:
P17181
Uniprot Name:
Interferon alpha/beta receptor 1
Molecular Weight:
63524.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717 ]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815 ]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.
Gene Name:
IFNAR2
Uniprot ID:
P48551
Uniprot Name:
Interferon alpha/beta receptor 2
Molecular Weight:
57758.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717 ]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815 ]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
Drug created on June 13, 2005 07:24 / Updated on July 11, 2017 16:38